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Interplay between MexAB-OprM 
and MexEF-OprN in clinical isolates 
of Pseudomonas aeruginosa
Gertrudis Horna 1,2, María López3, Humberto Guerra 2, Yolanda Saénz  3 & Joaquim Ruiz  1
MexAB-OprM and MexEF-OprN are Pseudomonas aeruginosa efflux pumps involved in the development 
of antibiotic resistance. Several studies developed with laboratory strains or using a few clinical isolates 
have reported that the regulation system of MexEF-OprN is involved in the final levels of MexAB-
OprM expression. Therefore, this study was aimed to determine the interplay between MexAB-OprM 
and MexEF-OprN in 90 out of 190 P. aeruginosa clinical isolates with an efflux pump overexpression 
phenotype. Regarding oprD, 33% (30/90) of isolates displayed relevant modifications (RM) defined 
as frameshift or premature stop, both related to carbapenem resistance. On the other hand, 33% of 
the isolates displayed RM in nalC, nalD or mexR, which were significantly associated with multidrug 
resistance (MDR), non-susceptibility to carbapenems, OprD alterations and strong biofilm production. 
Meanwhile, the RM in MexS were associated with presence of pigment (p = 0.004). Otherwise, when 
all the regulators were analysed together, the association between RM in MexAB-OprM regulators and 
MDR was only significant (p = 0.039) when mexS was the wild type. These data show the modulatory 
effect of MexEF-OprN on MexAB-OprM in a clinical population of P. aeruginosa. Further studies may 
contribute to design of novel molecules acting on this interplay to fight against antimicrobial resistance.
Pseudomonas aeruginosa is an opportunistic human pathogen characterised by intrinsic resistance to a vari-
ety of antimicrobial agents. This property results from the interplay between drug efflux systems and the low 
outer membrane permeability of this microorganism1–4. P. aeruginosa possesses at least 12 structural genes 
for multidrug efflux pumps belonging to the resistance – nodulation – cell division (RND) family of trans-
porters2. Of these, MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM efflux pumps have shown 
to be of clinical relevance3,5. The MexAB-OprM efflux system contributes to the intrinsic resistance of this 
organism to quinolones, tetracycline, chloramphenicol, novobiocin, macrolides and β-lactams, and its over-
expression confers cross-resistance or reduced susceptibility to several antibiotics2,6. In addition, it has been 
reported that MexAB-OprM exports quorum-sensing mediators such as acylhomoserine lactones including 
N-butyryl-L-homoserine lactone (C4-HSL), which induce the production of virulence factors, including pro-
teases, rhamnolipids, exotoxin A, exoenzyme S, and pyocyanin7. On the other hand, the MexEF-OprN system 
is not expressed during growth, and under laboratory conditions it is expressed in nfxC multidrug-resistant 
mutants2.
The presence of mutations in MexR, NalC and NalD repressors of MexAB-OprM up-regulate its expression8,9, 
whereas MexEF-OprN expression is enhanced by a positive regulator, MexT, and impaired by MexS expression7. 
In addition, MexT down-regulates oprD, the gene encoding the porin OprD which is used by imipenem for cell 
entry10,11.
Although, the concomitant overexpression of both efflux systems have previously been described in several 
P. aeruginosa clinical isolates, suggesting alternative regulation pathways12,13, the regulation system of MexEF- 
OprN is also involved in the final levels of MexAB-OprM expression1. Thus, it has been proposed that MexT 
down-regulates MexAB-OprM7,14. Nonetheless, further studies by Richardot et al.15 have shown that equivalent 
levels of mexT expression may or not drive to down-regulation of the mexB gene. This mexB down-regulation 
was associated with overexpression of mexE related to the lack of functionality of mexS, suggesting a more 
complex interrelation between the two efflux pumps15. In this sense, the NfxC type mutants (overexpressing 
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MexEF-OprN) exhibit low-level production of MexAB-OprM and virulence factors including a lower ability of 
biofilm formation15,16.
This inverse relationship between the expression of MexAB-OprM and the expression of MexEF-OprN could 
reflect an overlapping of antimicrobial substrates or similar cell-associated extruded products by any of these 
systems17. Nonetheless, this finding may also cause differences in virulence, antimicrobial resistance or specific 
properties1.
Overall, several studies have proposed the interaction between the two efflux systems2,7,16, however most of 
them have mainly been developed in laboratory strains or a few clinical isolates. The purpose of this study was 
to determine the interplay between MexAB-OprM and MexEF-OprN in antimicrobial resistance, the oprD gene, 
biofilm formation, swarming motility and pigment in a wide variety of clinical isolates of Pseudomonas aerugi-
nosa from two Peruvian hospitals.
Results and Discussion
Susceptibility to levofloxacin and efflux pump overexpression (EPO) phenotype. Overall, 58% 
(110/190) of the isolates were non-susceptible to levofloxacin (LVX), with no differences between the two hos-
pitals [Hospital Arzobispo Loayza, (HAL) and Hospital Nacional Cayetano Heredia (HNCH)]; 55% (62/112) in 
HNCH and 62% (48/78) in HAL. All isolates grew in the presence of phenylalanine-arginyl ß-naphthylamide 
(PAβN). The EPO phenotype was observed in 47% (90/190) of the isolates, with similar values in HNCH and 
HAL [45% (50/112), 51% (40/78) respectively].
The present data demonstrate an inverse relationship between multidrug resistance (MDR) and EPO 
(p = 0.0006). In addition, the EPO phenotype was associated with LVX and carbapenem susceptible isolates 
(p = 0.0093 and 0.0013, respectively) (Fig. 1). Most of the P. aeruginosa RND-efflux pumps may extrude fluo-
roquinolones. Therefore, increases in their activity (either that of an efflux pump alone or of two or more con-
comitantly) may be easily detected using a fluoroquinolone such as LVX together with an efflux pump inhibitor 
(EPI)1. Nonetheless, the present results agree with a limited effect of efflux pumps, by itself and in the absence of 
other mechanisms, on the change of the clinical strain classification from Susceptible to Intermediate / Resistant1. 
Additionally, these results may reflect the different substrate affinities presented by different efflux pumps1 and the 
different final effect on minimum inhibitory concentration (MIC) levels related to each P. aeruginosa efflux pump.
Mutations in oprD gene. The oprD gene was sequenced in all the isolates showing the EPO phenotype. 
Overall, 67% (60/90) of isolates displayed amino acid changes or deletions which did not affect the OprD 
frameshift. Thus, 7 isolates showed sequences identical to the P. aeruginosa PAO1 strain, 35% (21/60) isolates 
showed punctual mutations, and 53% (32/60) of the isolates displayed the amino acid deletions S373/G383. These 
amino acid deletions were presented in addition to several punctual mutations including V127L, E185Q, P186G, 
V189T, E202Q, I210A, E230K, S240T, N262T, T276A, A281G, K296Q, Q301E, R310E/G, G312R, A315G, K347M, V359L, S403A, 
Q424E as well as a series of changes between amino acid 372 and 383 (372V-DSSSSYAGL-383). Eighteen additional 
isolates presented these mutations and also possessed relevant modifications. Overall, punctual mutations were 
presented conforming sets (Table 1). Of these sets, those involving E202Q, I210A, E230K, S240T, N262T, A267S, A281G, 
K296Q, Q301E, R310G, (±V352I), V359L, (±Q424R) + 372V-DSSSSYAGL-383 (32 isolates, pattern A), T103S, K115T, F170L, 
E185Q, P186G, V189T, R310E, A315G, (±G425A) (19 isolates, pattern B) and V127L, E185Q, P186G, V189T, E202Q, I210A, 
E230K, S240T, N262T, T276A, A281G, K296Q, Q301E, R310E, (±G312R), A315G, L347M, S403A, Q424E + 372V-DSSSSYAGL-383 
(18 isolates, pattern C) were the most frequently detected. It has been described that these types of mutations have 
no effect on the development of resistance to carbapenems, including several of the most frequently found in 
present isolates such as T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, G425A (15 isolates) or T103S, K115T, 
F170L (4 isolates) in OprD18. Furthermore, the presence of the alteration 372V-DSSSSYAGL-383, shortening loop L7, 
Figure 1. Association of EPO phenotype with biofilm formation, swarming, pigment and antibiotic resistance. 
SBP: Strong biofilm producer; Swarming: Microorganisms showing swarming motility; Pigment: Presence of 
pigment; LVX: Resistance to levofloxacin; Carbapenem: resistance to carbapenems; MDR: Multidrug resistance; 
EPO: Efflux Pump Overexpression. In 2 isolates the MICI was >256 mg/L while the MICPABN was 256 mg/L, 
therefore the EPO phenotype was not determined. *p = 0.0093; **p = 0.0013; ***p = 0.006.
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has been related to increased susceptibility to meropenem19,20; therefore, these types of alterations were classified 
as “irrelevant modifications” when presented alone. The presence of a potential association has been suggested 
between specific amino acid substitutions in OprD and MLST profiles, observing a series of amino acid deletions 
plus a set of punctual mutations on analysing 12 isolates belonging to the ST11121. This pattern of OprD amino 
acid substitutions was almost concordant with the present pattern C, having also strong similarities with pattern 
A. Therefore, despite the absence of specific MLST determinations, the present results suggest the relevant pres-
ence of this high risk P. aeruginosa clone in the area. In a previous study22, the clonal relationships among these 
isolates was established, observing a high diversity (72 different clonal patterns). Nonetheless, 72.2% (13/18) of 
the isolates classified within pattern C, suggestive of belonging to ST111 were from HCNH while the remaining 
27.7% (5/18) were from HAL, accounting for 26% and 12.5% of the isolates analysed from each hospital. This 
finding is in accordance with Kim et al.21 who described differences in the prevalence of ST111 between different 
hospitals from the same area. In addition, another common set of amino acid substitutions (pattern B) very simi-
lar to those reported by Kim et al. 21 for P. aeruginosa ST298 and ST308 was also detected in 19 isolates.
On the other hand, alterations affecting porin functionality (lack of gene, premature STOPs or frameshifts) 
were classified as “relevant modifications”. Overall, 33% (30/90) of the isolates showed relevant modifications; 
40% (12/30) presenting frameshifts by base pair insertions and 47% (14/30) possessing premature stops in amino 
acid codons 65 and 49, and in four isolates no PCR amplification was obtained. Overall, the relevant modifi-
cations were strongly associated with carbapenem non-susceptible isolates (p < 0.0001) (Table 1). This finding 
correlates with other studies showing that carbapenem resistance is mainly associated with inactivation of the 
oprD gene21. In the present study, 33% of our isolates showed functional alterations containing mainly frameshifts 
and premature stops in the gene leading to truncated proteins, similar to the results reported by Kim et al.21. In 
addition, although PCR impairment due to DNA polymorphisms cannot be ruled out, the lack of amplification of 
oprD in four isolates could be explained by the presence of an insertion sequence (IS). In this sense the presence 
of disruption of the oprD gene by different ISs including the ISPa27, ISPa45, ISPa46, ISPa47, ISPa133, ISPa1328, 
ISPa1635, ISPst12 or ISPpu21 has previously been shown23,24.
Regulatory genes studies in MexAB-OprM. Three MexAB-OprM regulators were analysed. Regarding 
the mexR gene, 47% (42/90) of the isolates showed punctual mutations leading to amino acid changes, being 










(n = 40) Modifications (N)
Carbapenem
R 
(n = 28) S (n = 56) p
oprD
No mutation 7 5 2 — 0 7
Amino acid 
substitution 21 9 12
T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, G425A (15)b/







E202Q, I210A, E230K, S240T, N262T, A267S, A281G, K296Q, Q301E, R310G, 
V359L, Q424R + 372V-DSSSSYAGL-383 (21)/V127L, E185Q, P186G, V189T, 
E202Q, I210A, E230K, S240T, N262T, T276A, A281G, K296Q, Q301E, R310E, 
G312R, A315G, L347M, S403A, Q424E + 372V-DSSSSYAGL-383 (11)c.
2 30
Amino acid 
insertion 0 0 0 — 0 0
<0.0001d
Frameshift 12 3 9
insnt1087 (A) + T103S, K115T, F170L (2)/insnt1201–1205 (GTCCA) + T103S, 
K115T, F170L, E185Q, P186G, V189T, R310E, A315G (4)b/insnt941–942(GC) (2)/
insnt678 (G) + V127L, E185Q, P186G, V189T, E202Q, I210A, E230K, S240T, 
N262T, T276A, A281G, K296Q, Q301E, R310E, A315G, L347M, S403A, Q424E 
+ 372V-DSSSSYAG L-383 (1)c/insnt605–609 (CAACA) + E202Q, I210A, 
E230K, S240T, N262T, A267S, A281G, K296Q, Q301E, R310G, V352I, V359L + 
372V-DSSSSYAGL-383 (3).
7 0
Stop 14 12 2
W65* + V127L, E185Q, P186G, V189T, E202Q, I210A, E230K, S240T, 
N262T, T276A, A281G, K296Q, Q301E, R310E, A315G, L347M, S403A, 
Q424E + 372V-DSSSSYAGL-383 (6)c/Y49* + E202Q, I210A, E230K, S240T, 
N262T, A267S, A281G, K296Q, Q301E, R310G, V359L + 372V-DSSSSYAGL383- 
(8).
14 0
No amplification 4 4 0 — 2 2
Table 1. Modifications in the oprD gene of isolates with the EPO phenotype. HNCH: Hospital Nacional 
Cayetano Heredia, HAL: Hospital Arzobispo Loayza; N: Number; insnt: nucleotide insertion; *codon 
STOP. The slanted line (/) separates different patterns of modifications. Carbapenems R are isolates showing 
resistance or intermediate susceptibility to both imipenem and meropenem, while carbapenem S, are those 
isolates exhibiting susceptibility to both carbapenems. Six isolates with discordant resistance/susceptibility 
patterns among imipenem and meropenem were not included in either of the 2 columns. The amino acid 
changes located after a stop or frameshift are numbered following the sequence of the wild type strain without 
considering the presence of this stop or frameshift, and therefore do not represent the protein produced and 
are only reported for facilitating epidemiological interpretations. aIn bold are marked relevant modifications. 
bPattern B, very similar to the amino acid changes observed in ST298/ST30821. cPattern C, very similar to the 
amino acid changes observed in ST11121. dSignificant differences in carbapenem resistance levels between 
isolates possessing relevant and irrelevant modifications.
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remaining 10% (9/90) of isolates repeatedly did not amplify by PCR assay. Difficulties in PCR amplification may 
have been due to the presence of polymorphisms in the primers annealing regions, or the presence of inter-
nal DNA sequence modifications resulting in specific DNA conformation which impaired PCR amplification. 
However, the non amplification of the mexR gene was probably associated with the presence of a disrupting IS, 
such as IS21, which has previously been described as breaking mexR and leading to an increased transcription of 
the mexAB-oprM operon25.
Gene 









No mutationa 39 21 18 —
Amino acid substitution 42 23 19 V126E (39)/L131P (1)/V126E, L131P (1)/V126E, P143L (1)
Amino acid deletion 0 0 0
Amino acid insertion 0 0 0 —
Frameshift 0 0 0 —
No amplification 9 6 3 —
Stop 0 0 0 —
nalC
No mutation 10 4 6 —
Amino acid substitution 77 43 34
G71E, S209R (54)/G71E, A145V, S209R (5)/G71E, S209R, P210L (5)/G71E 
(4)/ G71E, A186T (4)/G71E, D79R, S209R (2)/G71E, H150Q, M151P, D152E, 
E153R, (1)/G71E, E153Q (1)/S209R (1)
Amino acid deletion 0 0 0 —
Amino acid insertion 0 0 0 —
Frameshift 1 1 0 Δnt234–243 + G71E
No amplification 2 2 0 —
Stop 0 0 0 —
nalD
No mutation 64 35 29 —
Amino acid substitution 8 6 2 T188A (4)/L44P (1)/D187S (1)/L194R (1)/Q134H, Q142H, A145P, D147H, E148K, C149R, H154P, R160K, D176E, D185Y, G206S, S209I (1)
Amino acid deletion 0 0 0 —
Amino acid insertion 0 0 0 —
Frameshift 16 8 8 Δnt397–398 (7)/Δnt263–279 (6)/Δnt391 (2)/Δnt451–461 (1)
No amplification 2 1 1
Stop 0 0 0 —
MexEF-OprN regulators
mexT
No mutationb 82 47 35 —
Amino acid substitution 3 1 2 D290E (1)/V269E (1)/G148A, G238R, A249P (1)
Amino acid deletion 0 0 0 —
Amino acid insertion 0 0 0 —
Frameshift 0 0 0 —
No amplification 5 2 3 —
Stop 0 0 0 —
mexS
No mutationb 50 31 19 —
Amino acid substitution 3 1 2 V73A (2)/ G224S (1)
Amino acid deletion 0 0 0 —
Amino acid insertion 0 0 0 —
Frameshift 0 0 0 —
No amplification 37 18 19 —
Stop 0 0 0 —
Table 2. Modifications in efflux pump regulators in isolates with the EPO phenotype. HNCH: Hospital 
Nacional Cayetano Heredia, HAL: Hospital Arzobispo Loayza, In bold are both marked relevant modifications 
as well as amino acid change patterns previously described by Quale et al.26. The slanted line (/) separates 
different patterns of modifications. The symbol Δnt means nucleotide deletion being noted the first and last 
nucleotides deleted. The amino acid changes located after a frameshift are numbered following the sequence 
of the wild type strain without considering the presence of this frameshift, and therefore do not represent the 
protein produced and are only reported for facilitating epidemiological interpretations. In parenthesis, the 
number of each specific alteration or combined alterations described. In all cases if a relevant modification 
was found the sequences are listed in this section, irrespectively of the remaining modifications detected. aIn 
isolates in which no mutation was observed, the MexAB-OprM regulator sequences were identical to those of P. 
aeruginosa PAO1 (GenBank: AE004091.2). bIn all isolates in which PCR amplification was obtained, the mexS 
and mexT genes were identical to those of P. aeruginosa PA14 (GenBank: CP000438).
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In relation to the nalC gene, 87% (77/90) of the isolates showed punctual mutations, being G71E (76/77) 
and S209R (67/77) the most frequent. In addition, one isolate showed a 10 base pair deletion from C234 to G243. 
Regarding nalD, 71% (64/90) of the isolates did not show modifications, and 20% (18/90) showed relevant mod-
ifications, being two base pair deletions (Δnt397–398) the most frequent in 39% (7/18) of the isolates (Table 2). 
Similar to our results, the presence of deletions in nalC has been previously shown in P. aeruginosa isolates26. In 
addition, Haenni et al.27 described different alterations in the nalD gene, including a gene disruption mediated 
by ISAs2 in isolates of P. aeruginosa. This finding may have occurred in two of our isolates that did not amplify 
this gene.
It has been described that genetic events such as frameshifts, disruptions or premature stops, which lead to 
loss of functionality of nalC, nalD or mexR are expected to up-regulate the mexAB-oprM operon25–28, and there-
fore were considered as relevant modifications. In the present study, 33% (30/90) of the isolates displayed rele-
vant modifications in the mexR, nalC or nalD genes which were significantly associated with MDR (p < 0.0001), 
carbapenem non-susceptible isolates (p < 0.0001) and relevant modifications of the oprD gene (p < 0.0001). In 
addition, these relevant modifications were significantly associated with strong biofilm producer (SBP) isolates 
(p = 0.006) [Fig. 2a].
Meanwhile, several of the amino acid changes detected, including some of the most frequently found, such 
as V126E detected in mexR in 39 isolates or G71E, S209R or G71E, A145V, S209R detected in nalC in 54 isolates and 5 
isolates, respectively, have previously been described in isolates not displaying MexAB-OprM overexpression26,29. 
Thus, mexR, nalC and nalD amino acid changes were classified as “irrelevant modifications”.
To fully determine the role of the modifications detected in the final expression levels of the mexA gene, 20 
isolates carrying different modifications in efflux-pump regulator genes were selected. The results showed that 8 
out of 11 isolates (1084, 1085, 1086, 1089, 1090, 1093, 1094, 1096) carrying relevant modifications in mexR, nalC 
or nalD presented relative mexA expression levels of 1.61 to 5.10 compared to PAO1. Meanwhile, only 2 out of 9 
isolates (1082 and 1092) carrying irrelevant modifications presented expression levels higher than PAO1 (1.51 to 
3.58) (Table 3). Therefore, on analysing the selected isolates together it was observed that relevant modifications 
were associated with higher mexA expression levels (p = 0.02).
Figure 2. Association of MexAB-OprM regulators and MexEF-OprN regulators with biofilm formation, 
swarming, pigment, oprD gene and antibiotic resistance. SBP: Strong biofilm producer; Swarming: 
Microorganisms showing swarming motility; Pigment: Presence of pigment; OprD (RM): Presence of relevant 
modifications in OprD (frameshifts + premature STOPs + no amplification); Carbapenem: resistance to 
carbapenems; MDR: Multidrug resistance. (a) MexAB-OprM regulators. IM: Irrelevant modifications (amino 
acid substitution + amino acid insertions + amino acid deletions); RM. Relevant Modifications (frameshifts + 
premature STOPs + no amplification); *p: 0.006; **p < 0.0001. (b) MexEF-OprN regulators. PA14: Sequence 
identical to PA14; NA: no amplification. *p: 0.004. Only the isolates presenting the genotypes PA14/PA14 (47 
isolates) and NA/PA14 (34 isolates) were analysed.
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Previous studies have reported that the MexAB-OprM efflux system contributes to the intrinsic resistance of 
P. aeruginosa to several antimicrobials such as quinolones, chloramphenicol and most β-lactams and its over-
expression contributes to MDR phenotypes1,2,30. Similarly, in the present study, isolates with relevant modifica-
tions in any of the MexAB-OprM regulators analysed were significantly associated with MDR. This finding is in 
accordance with the above mentioned different effect on final resistance levels of the overexpression of different 
efflux pumps, contributing to explain the observed lack of association between MDR (or LVX) and overall EPO, 
highlighting the role of MexAB-OprM in the development of antibiotic resistance.
In addition, we observed that the presence of relevant modifications in the MexAB-OprM regulators efflux 
system was significantly associated with reduced susceptibility to carbapenems (p < 0.0001) and relevant modifi-
cations in the oprD gene (p < 0.0001) (Table 4). This is in accordance with the role of the loss or low expression of 
OprD combined with the overexpression of this efflux system in carbapenem resistance mechanisms in P. aerug-
inosa isolates18,30–34. Interestingly, the presence of relevant modifications in MexAB-OprM regulators and OprD 
lack of functionality would seem to be independent phenomena. Nonetheless, the association observed may 
reflect an external pressure (e.g.: antibiotic consumption) affecting both systems. Furthermore, in agreement with 
previous studies in which overproduction of MexAB-OprM was correlated with biofilm production35, our results 
showed that the presence of relevant modifications in MexAB-OprM regulators was significantly associated with 
strong biofilm producer isolates.
Regulatory gene studies in MexEF-oprN. No modification in the mexT gene was observed in 90% 
(81/90) of the isolates (being identical to the sequence of the PA14 reference strain) and 3.3% (3/90) of the isolates 
presenting amino acid changes [D290E (1)/V269E (1)/G148A, G238R, A249P (1)]. The remaining 5.5% (5/90) of the 
isolates did not amplify the mexT gene. Meanwhile, 59% (53/90) of the isolates showed N249 in the mexS gene, 





nalC nalD mexR mexS mexT mexAa mexEa
1082 G71E, S209R WT WT WT NA 3.58 1.41
1083 WT WT WT WT WT 0.13 0.71
1084 G71E, A145V, S209R
NA WT NA-c WT 4.36 0.53
1085 G71E, S209R Δnt451–461 WT NA-c WT 1.84 0.45
1086 G71E, S209R Δnt397–398 V126E WT WT 5.10 7.92
1087 G71E, A145V, S209R
WT V126E NA-c WT 0.97 1.98






1089 G71E, S209R Δnt397–398 V126E WT WT 1.80 1.41
1090 G71E, S209R Δnt397–398 V126E WT WT 1.90 0.83
1091 G71E, S209R WT WT NA-c NA 0.34 0.37
1092 G71E, S209R
Q134H, Q142H, A145P, 
D147H, E148K, C149R, 
H154P, R160K, D176E, 
D185Y, G206S, S209I
V126E WT WT 1.51 0.53
1093 G71E, S209R Δnt397–398 V126E WT WT 3.74 0.83
1094 Δnt 234–243 WT WT NA-b WT 1.61 1.11
1095 G71E, S209R WT NA NA-b WT 1.04 8.92
1096 G71E, S209R Δnt391 V126E G224S WT 1.84 0.13
1097 G71E, S209R Δnt391 WT NA-b WT 0.38 0.91
1098 G71E, S209R, P210L
T188A WT WT WT 0.85 0.96
1099 G71E, A145V, S209R
WT V126E WT WT 1.26 0.76
1100 G71E, S209R WT NA WT WT 0.80 4.81
1101 WT WT WT NA-c WT 0.09 1.16
Table 3. Expression levels of mexA and mexE in Pseudomonas aeruginosa carrying specific alterations at 
MexAB-OprM/MexEF-OprN regulators. WT: wild type (nalC, nalD, mexR identical to that of PAO1; mexS 
and mexT identical to those of PA14); NA: No amplification; NA-b: In addition to no amplification of mexS, 
no amplification of either mexS N- and C-terminal regions (see panel b of Fig. 3); NA-c: In addition to 
no amplification of mexS, no amplification of the mexS C-terminal region (see panel c of Fig. 3). Relevant 
modifications are marked in bold. aRelative gene expression was calculated by 2−ΔΔCT method. The rpsL gene 
was used as reference, P. aeruginosa PAO1 strain as calibrator in mexA gene (value = 1) and P. aeruginosa 
PA14 strain was used as calibrator in mexE gene (value = 1). Expression levels increases ranging between 1.5 
and 2-fold were considered as borderline, and those increases in the expression levels >2 were classified as 
overexpression3,13.
www.nature.com/scientificreports/
7SCIenTIfIC REPORtS |         (2018) 8:16463  | DOI:10.1038/s41598-018-34694-z
Figure 3. PCR strategy used in the analysis of mexS gene. In all figure sections is first presented the scenario 
which explain the obtained results, and just below the scheme of the PCR reactions. When in grey a positive 
amplification was obtained, and the amplicon size is within the rectangle, when in blank, no amplification 
was obtained. In all cases the primers used are represented by thin arrows and numbered following the same 
numeration presented in Table 4. All positions arbitrarily refer to the first base of the mexS gene. The figure is 
not made to scale. Furthermore, in scenarios b and c, the presence of internal modifications in DNA sequence 
(affecting or not mexS functionality) may lead to DNA secondary structures which obstacle PCR amplification. 
(a) PCR amplification of mexS gene. (b) No amplification of mexS gene and amplification of N- and C-terminal 
regions. (c) No amplification of mexS gene and amplification of N-terminal regions. Two scenarios are 
considered. Scenario 1: a DNA sequence (represented with a weft filling rectangle) disrupt mexS after base 
position 650, allowing the amplification on the N-terminal region but avoiding that of full mexS gene as well 
as that of the C-terminal region. Scenario 2: a polymorphism (represented with “xxx”) avoid the annealing of 
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V73A (2) and G224S (1). All were considered as fully functional and able to inhibit the expression of MexEF-OprN 
(Table 2)15. The remaining 41% (37/90) of the isolates did not amplify the mexS gene (Table 2). Of these 37 iso-
lates, it was possible to amplify the mexS gene N- and C-terminal regions in 11 isolates, while in 23 isolates only 
the N-terminal region was amplified. In 3 isolates neither the N-nor C-terminal regions was amplified (Fig. 3).
Only two combinations of the mexS and mexT genes were further analysed: i) the mexS and mexT genes iden-
tical to those of PA14 (47 isolates), and ii) the non amplified mexS gene and mexT gene identical to that of PA14 
(34 isolates). The remaining scenarios were not further analysed due to the small numbers of isolates presenting 
the required characteristics (9 isolates). The second combination was significantly associated with the presence 
of pigment (p = 0.004) (Fig. 2b).
As mentioned above, amino acid changes both in mexS and mexT were classified as irrelevant modifications. 
Nonetheless, a direct effect of the amino acid substitutions detected on the functionality of these regulators cannot 
be ruled out15. Thus, the analysis of isolate 1096 presenting the amino acid change G224S showed mexE expression 
levels of 0.13, suggesting an enhancement of the inhibitory activity of MexS instead of a loss of MexS function. 
Meanwhile, in isolate 1088 carrying amino acid changes in MexT (G148A, G238R, A249P), the mexE expression 
values were of 0.64, within the range of isolates 1083, 1090, 1092,1093, 1099 which did not carry alterations in 
both MexS and MexT.
The mexE gene expression analyses showed that no amplification of mexS only correlated with mexE overex-
pression in 2 isolates (1087 and 1095). In isolate 1095, in which the expression levels of mexE were of 8.92, both 
N- and C-terminal regions were amplified while in isolate 1087 (mexE expression levels of 1.98) a PCR product 
was only obtained by amplifying the N-terminal region. In both cases, this may have occurred due to the pres-
ence of an IS disrupting the mexS gene27. Meanwhile, in other 6 isolates (1084, 1085, 1088, 1094, 1097, 1101) no 
deregulation of mexE was observed (mexE expression levels ranging from 0.53 to 1.16), despite the presence of a 
fully functional mexT, thereby suggesting the presence of polymorphisms in mexS primer annealing regions and/
or specific internal DNA conformation hampering PCR amplification, although a possible impairment of MexT 
activity in isolate 1088 related to specific amino acid changes cannot be ruled out. Nonetheless, it should be men-
tioned that a similar scenario of non mexE overexpression in the presence of fully functional MexT and inactive 
MexS has previously been described12. In the remaining isolate analysed (1091) with relevant alterations in mexS, 
the mexE expression levels of 0.37 were concordant with the absence of mexT amplification, which as mentioned 
above might be related to the presence of a disrupting internally inserted sequence (Table 3). In this line, Quale et 
al. detected up to 7 isolates showing diminished (arriving to 0) expression of mexE in which it was only possible 
to amplify the initial 462 bp of mexT, suggesting major mutations affecting this region26. Finally, in isolates 1086 
and 1100 a clear overexpression of mexE (expression levels of 7.92 and 4.81 respectively) was observed, despite 
the mexS and mexT genes being identical to those of PA14 (Table 3). This result shows the role of other regulators 
in the final expression levels of mexEF-oprN. In this line, modifications of the mvtA gene have been related to 
mexEF-oprN overexpression36.
Different from what was observed on analysing the MexAB-OprM regulators, no association was found 
between relevant modifications in MexEF-OprN regulators and MDR or the presence of an oprD gene frameshift. 
The only association observed was present among isolates with MexEF-OprN regulator relevant modifications 
and the presence of pigment (Fig. 2b). This finding disagrees with the reduced production of virulence factors 
such as biofilm formation, pyocyanin or rhamnolipids among others, in isolates overexpressing MexEF-OprN34,37. 
Nonetheless, it should be taken into account that despite the above commented impairment in the production of 
pyocyanin in isolates overexpressing MexEF-OprN, a role of MexEF-OprN in the excretion of intermediates of 
pyocyanin biosynthesis has been proposed38.
Interplay of the MexAB-OprM and MexEF-OprN. Previous studies have reported that C4-HSL induces 
the expression of the mexAB-oprM operon directly by binding at the MexR-MexAB-OprM operator-promoter 
region7. It has been reported that the nfxC mutant isolates overexpress MexEF-OprN, decreasing the produc-
tion of C4-HSL7, and subsequently those of MexAB-OprM, thereby having a negative effect on MexAB-OprM 
exported products and homoserine lactone-dependent virulence factors7. Likewise, the association between 
relevant modifications in MexAB-OprM regulators and MDR was only significant (p = 0.039) when mexS was 
wild type, and therefore able to exert a negative regulation effect on the expression levels of MexEF-OprN. 
Furthermore, in 2 out of 3 isolates (isolates 1095 and 1100) in which the presence of relevant modifications in the 
mexAB-OprM regulators did not result in mexA overexpression (expression levels of 1.04 and 0.8 respectively), 
the expression levels of mexE were of 4.81 and 8.92 (Table 3).
On the other hand, the final expression levels of MexAB-OprM and MexEF-OprN with isolate 1086 showed 
increased expression levels of both mexA (expression levels of 5.10) and mexE (expression levels of 7.92) (Table 3), 
which agree with the concomitant overexpression of both efflux systems previously described in several P. aerug-
inosa clinical isolates by different authors12,13.
Overall, the present data showed a relevant role of modifications leading to the loss of MexR, NalC and NalD 
functionality in the clinical isolates analysed, which were associated with higher levels of antibiotic resistance 
and different bacterial virulence including biofilm formation. The effect of these modifications on multidrug 
primer 2. (d) No amplification of Mex S gene and no amplification of N- and C- terminal regions. Two scenarios 
are considered. Scenario 1: the mexS gene has been deleted or is absent. Scenario 2: polymorphisms are present 
in both annealing position of primers 1 and 2. If this late option was right, the most probable is the presence of 
additional differences in the sequence.
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resistance levels was significantly higher in the presence of mexS amplification, highlighting the modulatory effect 
of mexEF-OprN overexpression on the final resistance phenotype.
Methods
Bacterial strains. We studied a total of 190 isolates of P. aeruginosa from clinical samples of patients attended 
at the HAL (78 isolates) and the HNCH (112 isolates) in Lima (Peru), from December 2012 to June 2013. In all 
cases only non-duplicated isolates from different patients were included in the study. The isolates were stored at 
−70 °C in skim milk medium (Oxoid, Hampshire, UK) until use. The clonal relationships, carbapenem suscepti-
bility and MDR levels, biofilm formation, swarming motility and pigment presence were determined in a previous 
study22. In all cases antibiotic susceptibility was classified, according CLSI breakpoints39. MDR was defined as 
resistance to three or more unrelated families of antibiotics (aminoglycosides, β-lactams, fluoroquinolones and 
polymyxin). The isolates intermediate or resistant to both imipenem and meropenem were classified as “carbape-
nem resistant”. Throughout the text the term “resistance” englobes resistant and intermediate isolates.
Efflux pump inhibition test. EPO was established by determining the effect of the EPI PAβN (Sigma 
Chemical, Co, St. Louis, MO) on the MICs of LVX. Thus, the MIC of LVX was established by the agar dilution 
method39 both with (MICPAβN) 20 µg/ml and without (MICI) of PAβN. An EPO phenotype was defined when 
MICI/MICPABN was >2 as previously described40. The effect of this concentration of PAβN on the viability of 
microorganisms was also assessed.
oprD gene amplification. Amplification of the oprD gene was performed by PCR (Table 4)41. Negative 
PCRs were performed twice in order to avoid false negative results. In all cases the PCR products were recovered 
and fully sequenced and compared to the reference strain PAO1 (GenBank: AE004091.2).
Efflux pumps gene regulators. The primers and PCR amplification conditions of the efflux regulator-encoding 
genes mexR, nalC, nalD, mexT and mexS were designed by Solé et al.9 with slight modifications of the annealing con-
ditions (Table 4). All PCR products were sequenced as above. When the PCR product did not amplify, the assay was 
performed twice to avoid false negative results. After that, negative PCR were considered to as genes with “relevant 
modifications”. The mexR, nalC and nalD genes were compared with those of P. aeruginosa strain PAO1 (GenBank: 
AE004091.2). However the mexT and mexS genes were analysed according to the full functional MexS and MexT of P. 
aeruginosa PA14 (GenBank: CP000438), because PAO1 lacks the functionality of those genes related to the presence 
Amplified 





Efflux pump regulators and oprD gene
mexR
mexR - F ATT CGC CAG TAA GCG GAT AC
1020 60 °C 9
mexR - R GGA TGA TGC CGT TCA CCT G
nalC
nalC - F TCA ACC CTA ACG AGA AAC GCT
814 69 °C 9
nalC - R TCC ACC TCA CCG AAC TGC
nalD
nalD - F GCG GCT AAA ATC GGT ACA CT
789 54 °C 9
nalD - R ACG TCC AGG TGG ATC TTG G
mexT
mexT - F TGC ATC ACG GGG TGA ATA AC
1398 60 °C 9
mexT - R GGT AGC GCC AGG AGA AGT G
mexS
mexS - F ATA CAG TCA CAA CCC ATG A
1153 60 °C 9
mexS - R TCA ACG ATC TGT GGA TCT
oprD
oprD - F GGC AGA GAT AAT TTC AAA ACC AA
1384 60 °C 41
oprD - R GTT GCC TGT CGG TCG ATT AC
N- and C- terminal regions of mexSa
N-terminal
mexS – F 1 ATA CAG TCA CAA CCC ATG A
115 60 °C
9
mexS – N 3 CTC TTC GCA TTT GAG GAC C This study
C-terminal
mexS – C 4 CAT CCT CGA CGA ATT GGG
448 60 °C
This study
mexS – R 2 TCA ACG ATC TGT GGA TCT 9
qRT-PCR analysis of efflux pumps
mexA
mexA - F GGC GAC AAC GCG GCG AAG G
203 60 °C 13
mexA - R CCT TCT GCT TGA CGC CTT CCT GC
mexE
mexE - F TCA TCC CAC TTC TCC TGG CGC TAC C
150 60 °C 13
mexE - R CGT CCC ACT CGT TCA GCG GTT GTT CGA TG
rpsL
rpsL - F CGG CAC TGC GTA AGG TAT GC
212 60 °C 42
rpsL - R CGT ACT TCG AAC GAC CCT GCT
Table 4. Primers used for PCR amplification. F1: Correspondence with Fig. 1; bp: base pair; F: Forward; R: 
reverse. aPrimers used to amplify the N- and C-terminal regions, respectively.
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of 8 bp insertion resulting in a frameshift in MexT and D249 in MexS15. To determine the presence of undetected 
insertions within to the mexS gene, a PCR strategy was designed. Briefly, in those isolates in which PCR product was 
repeatedly not obtained, two new PCR reactions were designed in order to amplify the N- and C-terminal regions, 
respectively (Table 4).
Efflux Pump expression. The expression levels of mexA and mexE were determined in 20 P. aeruginosa 
isolates representative of the different alterations encountered in the regulator genes. mRNA extraction and 
qRT-PCR were performed following the primers and methodology previously described (Table 4)13,42. In all cases, 
gene expression was normalised versus rpsL housekeeping gene and expression levels were indicated as a ratio to 
the expression level in strain PA01 (mexA) or PA14 (mexE).
Statistical analysis. The χ2 (Chi square test) was used to determine the presence of significant differ-
ences which were considered with a p value of ≤0.05. R studio version 3.4.0.was used for all statistical analyses. 
Resistant and intermediate isolates were classified together as “non-susceptible” for statistical analyses.
Compliance with ethical standards. The study was approved by the Ethical Committee of the Universidad 
Peruana Cayetano Heredia (Lima, Peru) and by the Ethical Committee of Hospital Clinic (Barcelona, Spain), and 
all experiments were performed in accordance with relevant guidelines.
All samples were obtained within routine clinical practice; no personal data was requested or available to 
researchers.
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